Sampa Dash

Dr. Sampa Dash

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
IPIrin Parvin
Irin Parvin
KSK. M. Shahunja
K. M. Shahunja
SKSoroar Hossain Khan
Soroar Hossain Khan
TATahmina Alam
Tahmina Alam
LSLubaba Shahrin
Lubaba Shahrin
MCMohammod Jobayer Chisti
Mohammod Jobayer Chisti
The efficacy of commonly used antibiotics for treating severe cholera has been compromised over time because of the reduced antibiotic susceptibility. This study aimed to describe the rate of detection of Vibrio cholerae O1 from fecal samples and antimicrobial susceptibility profiles of V. cholerae O1 serotypes to commonly used antibiotics. During January 2000–December 2018, V. cholerae O1 was detected in fecal samples of 7,472 patients. Vibrio cholerae O1 Inaba serotype was predominant, ranging from 60% to 86% during the period 2000–2006 except for 2003 and 2005 when the Ogawa serotype was predominant. Later on, the Ogawa serotype became predominant from 2007 to 2015, fluctuating between 52% and 100%. However, in 2016 and 2017, isolation rates declined to 2% and 1%, respectively, but surged again to 75% in 2018. Nearly 100% of V. cholerae O1 strains were sensitive to tetracycline during 2000–2004. Thereafter, a declining trend of sensitivity was observed to be continued and dropped down to < 6% during 2012–2017 and again increased to 76% in 2018. Susceptibility to azithromycin and ciprofloxacin was nearly 100%, and susceptibility to cotrimoxazole and furazolidone was 01% throughout the study period. We also found the emergence of resistance to erythromycin in 2005 and sensitivity to cotrimoxazole in 2018. Thus, the rapid decline of the sensitivity of V. cholerae O1 to tetracycline and a reversed peak after 6 years need continued monitoring and reporting.

15 August 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
SCSubhra Chakraborty
Subhra Chakraborty
SDSampa Dash
Sampa Dash
NANowrin Akbar Antara
Nowrin Akbar Antara
BRBharati Rani Roy
Bharati Rani Roy
SMShamim Al Mamun
Shamim Al Mamun
ASG FaruqueASG Faruque
ASG Faruque
(1) Shigella spp. (Shigella) is known for causing dysentery with blood in stool, but most children infected with Shigella have non-dysentery Shigella-associated diarrhea (NDSD). The World Health Organization recommends the use of antibiotics when diarrhea is bloody, leaving most NDSD cases untreated. The absence of dysentery may not indicate a low risk of death and severe morbidity. Rapid diagnosis and treatment of shigellosis in vulnerable, young children may be lifesaving. INSIGHT aims to determine the potential benefit of identifying NDSD cases (n = 296) and their outcomes compared to cases of Shigella dysentery [DS (n = 148)] and non-Shigella watery diarrhea [WD (n = 148)]. (2) Children seeking care at hospitals in Bangladesh will be enrolled and followed for 1 year (NDSD and DS) or 90 days (WD). We will determine the impact of NDSD on morbidity, mortality, gut health, nutritional status, and cognitive development compared to DS and WD in children and whether the simple “Rapid LAMP-based Diagnostic Test (RLDT)” can accelerate the detection and treatment of shigellosis in the clinical settings of rural Bangladesh. (3) INSIGHT will determine the impact of NDSD in children and determine if the treatment guidelines of shigellosis need to be revisited to improve clinical outcomes and the development of these children.

7 June 2023 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
MHMd Iqbal Hossain
Md Iqbal Hossain
SNSabiha Nasrin
Sabiha Nasrin
RDRina Das
Rina Das
PPParag Palit
Parag Palit
ASAl-Afroza Sultana
Al-Afroza Sultana
ASG FaruqueASG Faruque
ASG Faruque
: Campylobacter is a major cause of food-borne gastrointestinal illnesses worldwide, predominantly affecting children under 5 years of age. This study examined potential associations of symptomatic (with diarrhea) and asymptomatic (without diarrhea) Campylobacter infections with child growth among children under 5 years of age in South Asia. The Global Enteric Multicenter Study was conducted from 2007 to 2011 with a case-control design. Children were followed for 60 days after enrollment. Stool culture was performed to isolate Campylobacter spp. Among the 22,567 enrolled children, 9,439 were symptomatic, with 786 (8.28%) testing positive for Campylobacter. Conversely, 13,128 asymptomatic healthy controls were included, with 1,057 (8.05%) testing positive for Campylobacter. Growth faltering was observed in the symptomatic group, particularly among children aged 0–11 months (−0.19 height-for-age z score [HAZ]; 95% CI: −0.36, −0.03; P = 0.018) and 24–59 months (−0.16 HAZ; 95% CI: −0.28, −0.04; P = 0.010). However, in the asymptomatic group, growth faltering was observed only in the 24- to 59-month age group, in terms of HAZ (−0.15 HAZ; 95% CI: −0.24, −0.05; P = 0.002) and weight-for-height z score (−0.16; 95% CI: −0.26, −0.06; P = 0.001). These findings underscore the importance of immediate and enhanced introduction of preventive modalities to reduce the burden of Campylobacter infections and reduce their long-term sequelae.

13 June 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
SDSampa Dash
Sampa Dash
ESEva Sultana
Eva Sultana
MRMd. Razibur Rahman
Md. Razibur Rahman
FNFarina Naz
Farina Naz
MAMohammad Ali
Mohammad Ali
SCSubhra Chakraborty
Subhra Chakraborty
Background: Antimicrobial resistance, driven by inappropriate use and overuse of antibiotics, is a major public health threat. Diarrhea and respiratory illness are the leading causes of pediatric healthcare visits in low- and middle-income countries like Bangladesh. Despite clear WHO guidelines recommending limited use of antibiotics for these conditions, potentially inappropriate or non-prescription antibiotic use remains a concern. Methods: We interviewed caregivers of 3025 under-5 children via cellphones to assess common illnesses, associated care-seeking practices, and antibiotic use for diarrhea and respiratory illnesses experienced by their children in the prior 14 days. Caregivers were identified through hospital outpatient screening and were contacted over the phone for the interview at least two months after that hospital visit. Results: Among the participants, 116 (3.8%) reported diarrheal disease and 570 (18.8%) experienced respiratory illness during the preceding 2-week recall period. Among the children with diarrhea, 52.6% received antibiotics, and 73.8% obtained them over the counter from pharmacies. Among those with respiratory illness, 26.3% received antibiotics, and 58% procured them from local drugstores without a prescription from a registered physician. For diarrhea, azithromycin and metronidazole were the commonly used antibiotics, while for respiratory illness, cefixime and azithromycin were frequently used. Notably, 68% of the diarrheal children either sought care from local drugstores, were self-medicated, or did not receive any formal treatment. Conventional practice, long wait times at healthcare facilities, distance, and poverty were the main reasons for not seeking care from a registered healthcare provider. Conclusions: Understanding community-level antibiotic use and care-seeking behavior is essential to strengthening antibiotic stewardship and child health programs. Our findings suggest the need for context-sensitive community education, improved access to appropriate care, and enforcement of regulations restricting the over-the-counter sale of antibiotics to curb irrational and excessive antibiotic use.

19 September 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ASABU SADAT MOHAMMAD SAYEEM BIN SHAHID
ABU SADAT MOHAMMAD SAYEEM BIN SHAHID
SAShahnawaz Ahmed
Shahnawaz Ahmed
TRTanzina Tazul Renesa
Tanzina Tazul Renesa
AOAnindita Tasnim Onni
Anindita Tasnim Onni
SDSampa Dash
Sampa Dash
MCMohammod Jobayer Chisti
Mohammod Jobayer Chisti
Background: Fibersol-2 has some beneficial effects on human health. We aimed to evaluate the digestive tolerability and acceptability of Fibersol-2 in healthy and diarrheal children, as well as improvement in stool consistencies in young diarrheal children. Methods: Sixty children of either sex, aged 1–3 years having four groups (healthy children/low dose, healthy children/high dose, children with diarrhea/low dose and children with diarrhea/high dose) were enrolled into this exploratory study between 1st August to 23rd October 2017. Two presumptive doses, low (2.5g) and high (5g), twice daily with 50 ml drinking water for seven days were the interventions. Outcomes were to observe the development of possible abdominal symptoms, such as pain, distension, rumbling, and bloating during the intervention and post-intervention periods in healthy and diarrheal children as well as improvement in stool consistencies in diarrheal children. Results: Among the diarrheal children, the median (IQR) duration of resolution of diarrhea was 3.9 (2.9, 5.1) days vs. 3.5 (2.0, 8.0) days, p = 0.885; in low dose and high dose groups, respectively. Significant difference was observed in terms of abdominal pain (27% vs. 7%, p = 0.038) and distension (40% vs. 0%, p<0.001) in diarrheal children, compared to healthy children during the pre-intervention period. We also observed significant difference in respect of abdominal distension (23% vs. 0%, p = 0.011), rumbling (27% vs. 0%, p = 0.005) and bloating (43% vs. 3%, p = 0.001) in diarrheal children, compared to healthy children during the intervention period. However, no significant difference was observed in relation to abdominal pain (p = 0.347) and distension (p = 0.165) during the pre-intervention period, compared to the intervention period in diarrheal children. Moreover, no significant difference was observed during the post-intervention period for the diarrheal and healthy children. Conclusion: Fibersol-2 was found to be well tolerated in healthy and diarrheal children aged 1–3 years. Trial registration: This study was registered as part of a randomized trial at ClinicalTrials.gov, number NCT03565393. The authors confirmed that all ongoing and related trials for this drug/intervention were registered.

20 October 2026 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
FNFarina Naz
Farina Naz
SDSampa Dash
Sampa Dash
ESEva Sultana
Eva Sultana
MAMohammad Ali
Mohammad Ali
SDShaniram Das
Shaniram Das
SCSubhra Chakraborty
Subhra Chakraborty
: The rapid loop-mediated isothermal amplification-based diagnostic test (RLDT) has been validated as a simple, sensitive, and rapid tool for detecting Shigella spp. from fresh or frozen stool. When stool is unavailable or difficult to transport, rectal swabs (RSs) in Cary–Blair medium, stool collected in buffered glycerol saline (BGS), or stool-dipped swabs (SDSs) in Cary–Blair medium offer alternatives that can be easily collected and transported without maintaining a cold chain. This study evaluated the performance of RLDTs for detecting Shigella spp. from RSs, stool collected in BGS, and SDSs compared with fresh stool (FS). Paired RSs and FS were collected from 105 children younger than 5 years old at two hospitals in Bangladesh. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were determined along with the agreement between assays using kappa statistics. The RLDTs detected Shigella in approximately 38–40% of samples across all sample types. Rectal swabs in Cary–Blair medium and SDS each showed 97.6% sensitivity and 100% specificity, with PPVs of 100% and NPVs of 98.5% (RSs) and 98.4% (SDSs) compared with FS; stool collected in BGS samples demonstrated the highest sensitivity (100%) and NPV (100%), with 98.4% specificity and 97.6% PPV. All alternative specimen types showed almost perfect agreement with FS. The RLDT performed well using RSs, indicating a practical alternative to stool for detecting Shigella . The assay was also reliable with stool collected in BGS and SDSs. Broader adoption of RLDTs could improve diagnostic capacity and strengthen surveillance and control efforts.